Endometrial polyp Medical Services in China

Endometrial polyps are benign, localized overgrowths of endometrial glands and stroma that project into the uterine cavity. They arise from the functional layer of the endometrium and are typically attached by a stalk (pedunculated) or broad base (sessile). Though histologically benign in >95% of cases, atypical hyperplasia or malignancy—particularly in postmenopausal women or those with risk factors—must be ruled out. Pathogenesis involves dysregulated estrogen stimulation without adequate progesterone opposition, leading to abnormal endometrial proliferation. Localized alterations in sex hormone receptor expression (especially estrogen receptor alpha), angiogenic factors (e.g., VEGF), and inflammatory mediators further promote polyp formation and persistence. Epidemiologically, endometrial polyps affect approximately 10–25% of reproductive-age women and up to 35% of postmenopausal women undergoing evaluation for abnormal uterine bleeding. Prevalence rises with age, obesity, hypertension, and use of tamoxifen. Key modifiable risk factors include chronic anovulation (e.g., PCOS), unopposed estrogen exposure (exogenous or endogenous), obesity (adipose tissue aromatization increases bioavailable estradiol), hypertension, and diabetes mellitus. Non-modifiable risks include advancing age, prior pelvic infection, and history of infertility. Clinically, many polyps are asymptomatic and discovered incidentally during fertility workups or routine ultrasound. Symptomatic presentations include intermenstrual bleeding, menorrhagia, postmenopausal bleeding, and infertility—polyps impair embryo implantation by disrupting endometrial receptivity, altering local cytokine profiles, and causing mechanical interference. Recurrent pregnancy loss is also associated with untreated polyps. Quality of life impact is substantial: chronic bleeding causes fatigue and iron-deficiency anemia; anxiety around cancer risk and fertility uncertainty contributes to psychological distress; sexual discomfort due to spotting may strain relationships; and repeated diagnostic procedures (e.g., saline infusion sonography, hysteroscopy) add physical and emotional burden. In reproductive-aged patients, polyps significantly reduce natural conception rates and IVF success—studies show up to 50% improvement in live birth rates after hysteroscopic polypectomy. Early diagnosis via transvaginal ultrasound (with or without saline infusion) and definitive management through office-based or operative hysteroscopy remain cornerstones of care in reproductive medicine.

Endometrial polyps are benign, localized overgrowths of endometrial glands and stroma that project into the uterine cavity. They are common in reproductive-aged and perimenopausal women, with prevalence estimates ranging from 10% to 30% in asymptomatic populations and up to 45% in women presenting with abnormal uterine bleeding (AUB), infertility, or recurrent pregnancy loss. In the Department of Reproductive Medicine, management is individualized based on symptomatology, reproductive goals, polyp size and number, patient age, comorbidities, and risk for malignancy—particularly in postmenopausal women or those with risk factors such as obesity, unopposed estrogen exposure, or Lynch syndrome.

Conservative management is appropriate for asymptomatic, small (<1.5 cm), solitary polyps in premenopausal women without fertility concerns or risk factors for endometrial neoplasia. Serial surveillance via transvaginal ultrasound (TVUS) every 6–12 months may be considered, especially when polyps are incidentally detected. However, spontaneous regression occurs in only 2.7–12% of cases, and persistent polyps—even if asymptomatic—may impair endometrial receptivity and reduce implantation rates in assisted reproductive technology (ART) cycles. Therefore, conservative observation is rarely recommended for patients undergoing fertility evaluation or treatment.

Pharmacologic therapy has limited efficacy for definitive polyp resolution but plays a supportive role. Progestins—including oral micronized progesterone (200 mg daily for 10–14 days per cycle), medroxyprogesterone acetate (10 mg daily for 10–14 days), or levonorgestrel-releasing intrauterine systems (LNG-IUS)—may suppress polyp growth and alleviate AUB by counteracting estrogen-driven proliferation. While LNG-IUS demonstrates high efficacy in controlling menorrhagia and reducing polyp recurrence post-hysteroscopy (RR 0.38; 95% CI 0.21–0.69), it does not reliably eliminate existing polyps. Selective progesterone receptor modulators (SPRMs) like ulipristal acetate have shown transient reduction in polyp volume in small trials but are not approved for this indication and carry safety concerns regarding liver toxicity. Gonadotropin-releasing hormone agonists (GnRHa) are occasionally used preoperatively to shrink large or vascular polyps, particularly in cases of severe anemia or anticipated surgical complexity, though evidence remains limited and their use is off-label for polyp management.

Surgical hysteroscopic polypectomy remains the gold-standard treatment, especially for symptomatic polyps, infertility-related indications, or polyps >1.5 cm. Performed under direct visualization using either rigid or flexible hysteroscopes, the procedure involves mechanical resection with cold-loop or bipolar electrosurgical instruments. In reproductive medicine settings, emphasis is placed on preserving endometrial integrity: sharp dissection with micro-instruments or low-power bipolar energy minimizes thermal injury to the underlying basalis layer, thereby safeguarding future endometrial regeneration and receptivity. Outpatient hysteroscopy under local anesthesia (e.g., paracervical block + intracervical lidocaine) is increasingly standard, with success rates exceeding 95% and complication rates <1% (including uterine perforation, fluid overload, or infection). For complex cases—such as multiple, broad-based, or recurrent polyps—operative hysteroscopy in an operating room under general or spinal anesthesia is preferred. Histopathologic examination of all resected specimens is mandatory to exclude atypical hyperplasia or endometrial carcinoma, particularly in high-risk cohorts.

Treatment in China offers distinct advantages within reproductive medicine practice. First, China’s national standardization of hysteroscopic training—mandated by the National Health Commission—ensures widespread access to high-fidelity simulation-based certification and continuous competency assessment for gynecologists. Second, advanced hysteroscopic platforms (e.g., Karl Storz, Olympus, and domestic leaders like Wisonic and Urologix) are widely deployed across tier-1 to tier-3 hospitals, enabling real-time digital imaging, image enhancement (NBI, ICG), and integrated morcellation systems that improve precision and reduce operative time. Third, China’s robust ART infrastructure facilitates seamless integration of polypectomy into fertility pathways: same-cycle embryo transfer is routinely offered following hysteroscopic resection in select patients with favorable endometrial morphology, supported by Level I evidence from multicenter RCTs conducted in Beijing, Shanghai, and Guangzhou. Fourth, cost-effectiveness is notable—outpatient hysteroscopy costs approximately USD $300–$600, significantly lower than comparable procedures in Western countries, without compromising quality or safety metrics. Finally, China’s centralized electronic health record system enables longitudinal tracking of polyp recurrence, fertility outcomes, and long-term endometrial health, contributing to nationally aggregated outcome databases that inform evidence-based guidelines.

Post-procedural recovery emphasizes rapid return to normal activity while minimizing complications. Patients are advised to avoid sexual intercourse, tampon use, and immersion baths for 10–14 days to reduce infection risk. Mild cramping and light spotting for 3–7 days are expected; NSAIDs (e.g., ibuprofen 400 mg TID PRN) are first-line for analgesia. Hormonal suppression—typically with cyclic oral progestins or LNG-IUS—is initiated within 1–2 weeks post-polypectomy to inhibit recurrence, which affects 2.5–43% of patients within 12 months depending on baseline risk. For fertility patients, ovulation induction or timed intercourse may resume in the subsequent cycle if endometrial healing is confirmed via saline-infusion sonohysterography (SIS) or office hysteroscopy. Nutritional counseling focuses on anti-inflammatory dietary patterns (rich in omega-3 fatty acids, fiber, and antioxidants) and weight optimization in overweight patients, given the strong association between BMI >25 kg/m² and polyp recurrence. Follow-up includes TVUS at 3 months to assess for recurrence and, in infertility cases, endometrial receptivity testing (ERA) or chronic endometritis screening (CD138 immunohistochemistry) if implantation failure persists. Long-term surveillance is recommended for high-risk individuals, including annual endometrial sampling or hysteroscopy every 2–3 years in postmenopausal women with prior polyps.